Trial Profile
An Open Label Trial to Assess the Safety and Efficacy of KRN23, an Investigational Antibody to FGF23, in a Single Pediatric Patient With Epidermal Nevus Syndrome (ENS) and Associated Hypophosphatemic Rickets
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 08 Oct 2022
Price :
$35
*
At a glance
- Drugs Burosumab (Primary)
- Indications Nevus; X-linked dominant hypophosphataemic rickets
- Focus Therapeutic Use
- 20 Sep 2021 Status changed from active, no longer recruiting to completed.
- 12 Aug 2020 Planned End Date changed from 15 Dec 2021 to 31 Jan 2022.
- 12 Aug 2020 Planned primary completion date changed from 15 Jun 2021 to 31 Jul 2021.